VRCA - Verrica Pharmaceuticals Inc.
| Previous Close | 14.60 |
| Open | 14.83 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1000 |
| Day's Range | 14.69 - 15.47 |
| 52 Week Range | 6.44 - 15.94 |
| Volume | 33,197 |
| Avg. Volume | 52,518 |
| Market Cap | 384.06M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.12 |
| Earnings Date | Aug 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.00 |
- GlobeNewswire
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced the presentation of positive data from three abstracts evaluating the efficacy and safety of VP-102 (cantharidin 0.7% Topical Solution), the Company’s lead product candidate for the treatment of molluscum contagiosum and common warts.
- GlobeNewswire
Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced it has appointed Eugene Scavola to the role of Executive Vice President, Technical Operations. An accomplished life sciences industry veteran, Mr. Scavola will spearhead Verrica’s Chemistry Manufacturing and Controls (CMC) functions. In this capacity, he will lead operational and technical aspects of product development, contract manufacturing, and analytical development activities for all Verrica product candidates.
- GlobeNewswire
Verrica Pharmaceuticals Announces Leadership Team Update
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that the Company has appointed A. Brian Davis as its new Chief Financial Officer (CFO). Mr. Davis replaces Chris Degnan, who is leaving the organization to pursue an opportunity in the oncology sector. Mr. Davis joins Verrica with nearly 15 years of experience as a CFO for publicly traded, commercial- and development-stage biopharmaceutical companies, and more than 25 years as a financial professional in the life sciences industry.
- Zacks
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
- Zacks
Will Verrica Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor Verrica Pharmaceuticals.
- Zacks
FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD
FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.
- Zacks
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
- GlobeNewswire
Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy, for the treatment of molluscum contagiosum (molluscum). No FDA-approved treatments are currently available for molluscum, a common, highly contagious skin disease affecting an estimated 6 million people in the United States, primarily children.
- Zacks
Small Drug Stock Outlook: Innovation Holds the Key to Growth
Small Drug Stock Outlook: Innovation Holds the Key to Growth
- Simply Wall St.
Have Insiders Been Buying Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that Ted White, Verrica President and CEO, will present a business overview and review of the company’s pipeline programs at the H.C. Wainwright 21st Annual Global Investment Conference in New York, NY on Monday, September 9, 2019 at 3:00 p.m. ET. A live audio webcast of the event will be available in the Investors/Events & Presentations section of the Verrica website at http://www.verrica.com. Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases.
- GlobeNewswire
Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts
Verrica Pharmaceuticals Inc. (Verrica) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that the first patient has been enrolled in the company’s Phase 2 ‘CARE’ clinical trial evaluating the optimal dose regimen, efficacy, safety and tolerability of VP-102, a novel topical therapy containing a solution of 0.7% cantharidin in a proprietary single-use applicator, in patients with external genital warts.
- Benzinga
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...
- GlobeNewswire
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts
Verrica Pharmaceuticals Inc. (Verrica) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced positive topline results from its COVE-1 Phase 2 open label clinical study of VP-102 for the treatment of verruca vulgaris, or common warts. COVE-1 included two cohorts that evaluated the safety and efficacy of VP-102, a novel topical therapy containing a solution of 0.7% cantharidin in a proprietary single-use applicator, in subjects with up to six warts.
- Simply Wall St.
What Type Of Shareholder Owns Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA)?
The big shareholder groups in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have power over the company. Institutions...
- GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the Jefferies 2019 Healthcare Conference
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that Ted White, Verrica President and CEO, will present a business overview of the company’s pipeline programs at the Jefferies 2019 Healthcare Conference in New York, NY on Tuesday, June 4, 2019 at 3:00 p.m. ET. A live audio webcast of the event will be available in the Investors/Events & Presentations section of the Verrica website at http://www.verrica.com/. Verrica is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases.
- GlobeNewswire
Verrica Pharmaceuticals Reports First Quarter 2019 Financial Results
-Reported positive topline data from pivotal Phase 3 clinical trials of VP-102 for the treatment of molluscum contagiosum -Preparing to submit NDA in second half of 2019 WEST.
- GlobeNewswire
Verrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today announced that Ted White, Verrica President and CEO, will present a business overview of the company’s pipeline programs at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas, NV on Tuesday, May 14, 2019 at 2:35 p.m. PT. A live audio webcast of both events will be available in the Investors/Events & Presentations section of the Verrica website at http://www.verrica.com/.
- GlobeNewswire
Verrica Reports Fourth Quarter and Full Year 2018 Financial Results
WEST CHESTER, Pa., March 07, 2019 -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization.
- GlobeNewswire
Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
Verrica Pharmaceuticals Inc. (Verrica) (VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, today presented data from the company’s pivotal Phase 3 CAMP-1 and CAMP-2 trials of lead product candidate, VP-102, at the American Academy of Dermatology (AAD) annual meeting being held in Washington, DC from March 1-5. Both trials of VP-102 in patients with molluscum contagiosum (molluscum) successfully met their primary endpoints.
- GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference
WEST CHESTER, Pa., Feb. 27, 2019 -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing.
- GlobeNewswire
Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
WEST CHESTER, Pa., Feb. 12, 2019 -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on the development of innovative pharmaceutical.
- GlobeNewswire
Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced the appointment of Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy. "We are delighted to welcome Neil to our team and look forward to leveraging his deep industry experience as the company prepares for the potential launch of VP-102 for molluscum contagiosum," commented Ted White, President and Chief Executive Officer of Verrica. Mr. DeHenes brings to Verrica extensive experience in end-to-end commercialization support across the design, evaluation, implementation, and execution of channel strategy, patient services, co-pay offerings, third party logistics, and government program operations.
- GlobeNewswire
Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum
WEST CHESTER, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced positive topline results from its Phase 3 CAMP-1 and CAMP-2 pivotal trials with VP-102 for the treatment of molluscum contagiosum (molluscum). Both clinical trials evaluated the safety and efficacy of VP-102, a proprietary drug-device combination containing a novel topical solution of 0.7% cantharidin, compared to placebo. In each trial, VP-102 exhibited a clinically and statistically significant proportion of subjects demonstrating complete clearance of all treatable molluscum lesions versus placebo.
